share_log

HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $4 Price Target

Benzinga ·  Jun 21, 2023 23:46

HC Wainwright & Co. analyst Edward White reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $4 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment